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Erratum 
Please be advised that there is an error in Table I of 
“The  Role  of  HER2-targeted  Therapies  in  Women 
with HER2-Overexpressing Metastatic Breast Cancer” 
by Dent et al. which appeared in Current Oncology 





Slamon et al., 2001 18
(n=469)
Trial arms 













Median orr (%) 50 32 61 34
p<0.001 p=0.0002
Median dr (months) 9.1 6.1 11.7 5.7
p<0.001 p=0.009
Median ttp (months) 7.4 4.6 11.7 6.1
p<0.001 p=0.0001





orr = objective response rate; dr = duration of response; ttp = time to progression; os = overall survival.
26 online. The median ttp in the Slamon et al. trial in 
the column labeled “Trastuzumab AND [paclitaxel OR 
(anthracycline AND cyclophosphamide)]” should read 7.4 
not 4.7 as originally printed.  The corrected version of 
the table can be found below.